RIGL
vs
S&P 500
RIGL
S&P 500
Over the past 12 months, RIGL has significantly outperformed S&P 500, delivering a return of +113% compared to the S&P 500's +12% growth.
Stocks Performance
RIGL vs S&P 500
Performance Gap
RIGL vs S&P 500
Performance By Year
RIGL vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Rigel Pharmaceuticals Inc
Glance View
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 165 full-time employees. The company went IPO on 2000-11-29. The firm is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The firm's research focuses on signaling pathways that are critical to disease mechanisms. The firm's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). The Company’s product is also commercially available in Europe, the United Kingdom (UK) (TAVLESSE) and Canada (TAVALISSE) for the treatment of chronic ITP in adult patients. Its clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company (Lilly).
